Patents Issued in February 6, 2020
  • METHODS OF INHIBITING VIRUSES USING COMPOSITIONS TARGETING TSG101-UBIQUITIN INTERACTION
    Publication number: 20200038388
    Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 6, 2020
    Applicants: The Research Foundation for the State University of New York, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Carol Carter, Lorna Erlich, Nico Tjandra, Madeleine Davison
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20200038389
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 6, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant
  • ORAL TABLET FORMULATION OF LENALIDOMIDE
    Publication number: 20200038390
    Abstract: The present disclosure relates to an oral tablet composition comprising lenalidomide and a method for preparing the same. More particularly, the present disclosure relates to a tablet-type composition and a method for preparing the same wherein the composition exhibits physicochemical equivalence with lenalidomide preparations of hard capsules, has the same pharmacological, therapeutic effect in non-clinical studies and bioequivalence studies, and also has improved ease of taking, handling, safety and the like.
    Type: Application
    Filed: September 11, 2017
    Publication date: February 6, 2020
    Applicant: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Sang Yeob PARK, Hye Jung LIM, Sa Won LEE, Min Hyo SEO
  • 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones
    Publication number: 20200038391
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
  • TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE
    Publication number: 20200038392
    Abstract: The present invention provides topical, e.g., dermal, pharmaceutical compositions comprising an active agent. The present invention further provides methods of preparing such compositions and methods of treating a disease, disorder, or condition, such as a skin disease, using the same.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Inventors: Todd Brady, David Clark, Susan Macdonald, Stephen Gitu Machatha, Cameron Robert Stevenson, Charles Rodney Greenaway Evans
  • APOMORPHINE PLUS BUSPIRONE COMBINATION FOR MEMORY REVIVAL
    Publication number: 20200038393
    Abstract: The invention introduces a method of inhibiting abuse potential and psychosis associated with long term use of apomorphine. Apomorphine used for the treatment of motor symptoms in Parkinson's disease produces addiction, and psychosis. The present method shows that apomorphine plus buspirone combination in the ratio of 1:1 will not produce psychosis. The combination will not be addictive too.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 6, 2020
    Inventors: Huma Ikram, 2. Darakhshan Jabeen Haleem, Rumaisa Zakir
  • PHARMACEUTICAL SALT OF ANTITUMOR HETEROCYCLIC IMIDAZOLE COMPOUND
    Publication number: 20200038394
    Abstract: The present invention relates to the field of pharmaceutical synthesis, and in particular to an antitumor heterocyclic imidazole compound (I), namely: a pharmaceutical salt of 4-(3-(4-(1H-imidazo[4,5-b]pyridine-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazine-1(dihydro)-ketone, a preparation method therefor, a pharmaceutical composition thereof and a use thereof in the preparation of antitumor drugs. The pharmaceutical salt of the compound (I) in the present invention may be used in the preparation of a medicament for the treatment or prevention of conditions which can be improved by inhibiting PARP activity.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 6, 2020
    Inventors: Xing FAN, Wenhua LI, Jihong QIN
  • METHOD OF REDUCING NEUTROPENIA
    Publication number: 20200038395
    Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.
    Type: Application
    Filed: February 1, 2018
    Publication date: February 6, 2020
    Inventors: Ramon MOHANLAL, Lan HUANG, George Kenneth LLOYD
  • TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM
    Publication number: 20200038396
    Abstract: A process of production of trazodone or trazodone hydrochloride that comprises; (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 6, 2020
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Marcello Marchetti, Tommaso Iacoangeli, Giovanni Battista Ciottoli, Giuseppe Biondi
  • PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA
    Publication number: 20200038397
    Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)?)-1-(4-fluoro-S-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an ?2 agonist for preventing or treating glaucoma.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 6, 2020
    Applicant: KOWA COMPANY, LTD.
    Inventors: Yoshio KANEKO, Masayuki OHTA
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
    Publication number: 20200038398
    Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and a second anticancer agent such as osimertinib, pazopanib, navitoclax, palbociclib, or olaparib. The invention further relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and conventional radiotherapy or stereotactic body radiotherapy.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 6, 2020
    Inventors: Susan D. Bromley, Francesco Parlati, Matthew I. Gross, Keith Orford
  • FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION
    Publication number: 20200038399
    Abstract: Pharmaceutical formulations for treating bacterial or fungal infections comprising iclaprim or its enantiomers and a sulfonamide antibiotic, and treatment and manufacturing methods, kits and dosage forms thereof, are provided.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Inventors: David Huang, Sergio Lociuro, Khalid Islam, Keith Bostian
  • DRUG EFFECTIVE FOR LYMPHOGENOUS DRUG ADMINISTRATING METHOD
    Publication number: 20200038400
    Abstract: Provided is a pharmaceutical composition suitable for administration of anticancer drugs into lymph nodes by means of lymphatic drug delivery systems. A pharmaceutical composition for therapeutic or prophylactic treatment of cancer to be administered into lymph nodes, comprising at least one anticancer drug selected from the group consisting of antimetabolites and anticancer plant alkaloids as an active ingredient.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 6, 2020
    Applicants: TOHOKU UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Tetsuya KODAMA, Shiro MORI, Go NOHARA
  • Therapeutic Compositions
    Publication number: 20200038401
    Abstract: The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventor: Martine Clozel
  • SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS
    Publication number: 20200038402
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 6, 2020
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
    Publication number: 20200038403
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Yam B. POUDEL, Sanjeev GANGWAR, Liqi HE, Prasanna SIVAPRAKASAM, Matthias BROEKEMA, Matthew COX, Christine M. TARBY, Qian ZHANG
  • METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
    Publication number: 20200038404
    Abstract: The present invention provides active metablites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 6, 2020
    Inventors: James D. Rodgers, Argyrios G. Arvanitis, Jack Guoen Shi, Stacey Shepard
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20200038405
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY
  • 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY
    Publication number: 20200038406
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 6, 2020
    Applicant: Oncoceutics, Inc.
    Inventors: Martin STOGNIEW, Joshua E. ALLEN
  • PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE
    Publication number: 20200038407
    Abstract: An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.
    Type: Application
    Filed: July 11, 2019
    Publication date: February 6, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takashi TOMIMATSU, Kensuke OKAZAKI, Yumi OGAWA, Takahiro YAMAMURA
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20200038408
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 6, 2020
    Inventor: Herriot Tabuteau
  • AMINOPYRIMIDINYL COMPOUNDS
    Publication number: 20200038409
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
  • METHODS FOR TREATING NEUROPATHY
    Publication number: 20200038410
    Abstract: Methods of treating, controlling, and delaying the onset and progression of neuropathy, including neuropathic pain associated with metabolic syndrome, including but not limited to obesity associated therewith. The methods include administering a liver X receptor agonist to the subject.
    Type: Application
    Filed: July 26, 2019
    Publication date: February 6, 2020
    Inventor: Virginie Mansuy-Aubert
  • METHODS OF TREATING TESTOSTERONE DEFICIENCY
    Publication number: 20200038411
    Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed to provide optimum plasma testosterone levels over an extended period.
    Type: Application
    Filed: March 7, 2019
    Publication date: February 6, 2020
    Inventors: Robert E. DUDLEY, Theodore DANOFF, James A. LONGSTRETH
  • METHODS OF TREATING ALZHEIMER'S DISEASE USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038412
    Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of Alzheimer's disease (AD) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • METHODS OF TREATING PARKINSON'S DISEASE USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038413
    Abstract: The present application relates generally to compositions and methods for treating and/or preventing Parkinson's disease and symptoms related thereto with with compositions comprising at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • METHODS OF TREATING CONSTIPATION USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038414
    Abstract: This invention relates to methods of treating constipation and constipation-related symptoms in a subject in need. The methods, which utilize a patient-specific “fixed dose” of an aminosterol, comprise administering a therapeutically effective dose of an aminosterol to a subject in need.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING ERECTILE DYSFUNCTION
    Publication number: 20200038415
    Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of erectile dysfunction (ED) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloft
  • METHODS OF TREATING CARDIAC CONDUCTION DEFECTS USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038416
    Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of cardiac conduction defects (CCDs) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • METHODS AND COMPOSITIONS FOR TREATING COGNITIVE IMPAIRMENT
    Publication number: 20200038417
    Abstract: This invention relates to methods of treating, preventing, and/or slowing the onset or progression of cognitive impairment and/or a cognitive impairment related symptom in a subject in need. The methods, which utilize a patient-specific “fixed dose” of an aminosterol, comprise administering a therapeutically effective dose of an aminosterol to a subject in need.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • METHODS OF TREATING AUTISM SPECTRUM DISORDER USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038418
    Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of autism spectrum disorder (ASD) and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • METHODS OF TREATING MULTIPLE SYSTEM ATROPHY USING AMINOSTEROL COMPOSITIONS
    Publication number: 20200038419
    Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of multiple system atrophy (MSA) and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION
    Publication number: 20200038420
    Abstract: The present application relates generally to methods for treating, preventing, and/or slowing the onset or progression of depression and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE
    Publication number: 20200038421
    Abstract: The present invention generally relates to a sugar alcohol and cannabinoid complex, and methods to prepare this complex from cannabinoid oil comprising at least one cannabinoid. The complex is in solid form and may be used in food, pharmaceutical, cosmetic formulations, and medical devices wherein solid forms of cannabinoid are desirable. This complex also enhances release of active cannabinoids in oral consumption. Methods to make this complex are also disclosed.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 6, 2020
    Inventors: George Anastassov, Lekhram Changoer
  • A COMPOSITION WITH MOBILITY BENEFITS IN AGEING, HEALTHY SUBJECTS
    Publication number: 20200038422
    Abstract: The invention provides a composition useful in maintaining or improving mobility, preferably joint function and muscle strength in ageing, healthy subjects. The composition includes specific amounts of glucosamine or a pharmaceutically-acceptable derivative thereof, calcium, vitamin C, vitamin D and zinc. Also provided is the composition in the form of a powdered food product, and a beverage product comprising the composition in the form of a powder which has been reconstituted in a liquid. Also provided is the use of the composition or food or beverage product in maintaining or improving mobility, preferably joint function and muscle strength in ageing, healthy subjects.
    Type: Application
    Filed: April 12, 2018
    Publication date: February 6, 2020
    Inventors: Marie Noelle Horcajada, Jan Biehl, Liya Denney, Laurence Donato-Capel, Benoit Idieder
  • USE OF 6-O-(C8-C20 ALKYL ESTER) OF 1-O-(C1-C6 ALKYL)-ß-D-GLUCOSIDE AS AN AGENT FOR PROTECTING THE SKIN
    Publication number: 20200038423
    Abstract: The present invention relates to the use of 6-O-(C8-C20 alkyl ester) of 1-O-(C1-C6 alkyl)-?-D-glucoside and in particular 6-O-lauroyl of 1-O-n-butyl-?-D-glucoside as an agent for protecting the skin and/or mucous membranes. The invention relates specifically to a cosmetic, dermatological and/or pharmaceutical composition, intended for topical use, which can be used for skin care and/or treatment.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 6, 2020
    Applicant: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Sylvie DAUNES MARION, Marie Florence GALLIANO, Hélène HERNANDEZ-PIGEON, Stéphane POIGNY
  • NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES
    Publication number: 20200038424
    Abstract: The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 6, 2020
    Inventors: Michio Hirano, Caterina Garone, Ramon Marti
  • MICRORNA 19A/19B FOR USE IN TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH BONE LOSS OR REDUCED MUSCLE FUNCTION
    Publication number: 20200038425
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Application
    Filed: April 6, 2018
    Publication date: February 6, 2020
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito
  • SYNERGISTIC COMBINATION OF OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC FOR TREATING CANCER
    Publication number: 20200038426
    Abstract: Compositions and methods for treating cancers are provided which comprise administering a combination of antineoplastic agents, wherein the combination comprises protein kinase inhibitor, anthracycline, nucleoside analog, apoptosis-inducing molecular therapeutic or alkylating agent chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. Preferably, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 6, 2020
    Inventors: Bellur PRABHAKAR, Sidney HOPPS, Aditi MATHUR, Fei YUE, Shikha SAINI
  • CYCLIC NUCLEIC ACID MOLECULE HAVING GENE EXPRESSION CONTROL FUNCTION
    Publication number: 20200038427
    Abstract: The present invention aims to provide a nucleic acid molecule having improved stability in serum and capable of exhibiting a gene expression regulation function after transfer into the cell. A cyclic nucleic acid molecule represented by the following formula (A): wherein each symbol is as described in the DESCRIPTION can be synthesized easily at a low cost, and can inhibit the translation of a protein encoded by the gene. Since the cyclic nucleic acid molecule of the present invention can inhibit the expression of a target gene as described above, for example, it is useful as a pharmaceutical product, a diagnostic agent, an agricultural chemical, and a tool for conducting research on agriculture, medical science, life science, and the like.
    Type: Application
    Filed: March 30, 2018
    Publication date: February 6, 2020
    Applicant: BONAC CORPORATION
    Inventors: Tadaaki OHGI, Chisato EMURA, Junichi YASUOKA, Yutaka EGUCHI
  • CANCER CELL ADHESION ACTIVITY INHIBITOR
    Publication number: 20200038428
    Abstract: The purpose of the present invention is to provide a drug that is capable of effectively inhibiting adhesion activity, growth, and engraftment of cancer cells, using an oligodeoxynucleotide (ODN) in which phosphodiester bonds are phosphorothioated (S-configured). Adhesion activity, growth inhibitory capacity, and engraftment inhibitory capacity of cancer cells are rapidly improved as a result of S-configured ODN being formed into a composite with a polysaccharide having a ?-1,3-glucan backbone.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 6, 2020
    Applicant: NAPAJEN PHARMA, INC.
    Inventors: Sadaharu HIGUCHI, Kanako AMANO, Maki Ushida, Hironori ANDO
  • P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION
    Publication number: 20200038429
    Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
    Type: Application
    Filed: April 19, 2018
    Publication date: February 6, 2020
    Applicants: Bio-Path Holdings, Inc., Thomas Jefferson University
    Inventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
  • IN VITRO HEPARIN AND HEPARAN SULFATE COMPOSITIONS AND METHODS OF MAKING AND USING
    Publication number: 20200038430
    Abstract: Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.
    Type: Application
    Filed: December 15, 2017
    Publication date: February 6, 2020
    Inventors: Charles GLASS, Bryan THACKER, Jeffrey ESKO
  • TREATMENT OF MYELOSUPPRESSION
    Publication number: 20200038431
    Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 6, 2020
    Inventor: Stephen Marcus
  • HYALURONIC ACID COATED CHIMERIC VIRAL/NONVIRAL NANOPARTICLES
    Publication number: 20200038432
    Abstract: The disclosure provides for hyaluronic acid functionalized chimeric viral/nonviral nanoparticles, and uses thereof.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Young Jik Kwon, Margaret Lugin
  • AQUEOUS COMPOSITION DERIVED FROM SEAWATER AND SEAWEED
    Publication number: 20200038433
    Abstract: An aqueous composition for the stimulation of the immune system for the purpose of preventing at least one of the diseases provoked by the invasion of one or several pathogenic agents through the skin, the eye or a mucous membrane. The aqueous composition is obtained from seawater and includes a sulphated polysaccharide contained in a seaweed.
    Type: Application
    Filed: September 26, 2017
    Publication date: February 6, 2020
    Inventors: ROXANE FAGON, MELODY DUTOT-WOLF, CAROLINE TANTER, MARC HEMON
  • PRODUCT FOR OBESITY TREATMENT
    Publication number: 20200038434
    Abstract: A product containing a boron compound for use in obesity treatment. By means of the present invention, a product can be obtained for obesity treatment which is not toxic to the other tissues and organs of the body. In obtaining the said product, sodium pentaborate pentahydrate, which is a poloxamer derivative, are used.
    Type: Application
    Filed: March 7, 2018
    Publication date: February 6, 2020
    Applicant: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin SAHIN, Nezaket TURKEL SESLI, Aysu YILMAZ
  • MINERAL, NUTRITIONAL, COSMETIC, PHARMACEUTICAL, AND AGRICULTURAL COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
    Publication number: 20200038435
    Abstract: Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 6, 2020
    Applicant: Core Intellectual Properties Holdings, LLC
    Inventors: Roger D. Blotsky, Ramon Figueroa
  • METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY
    Publication number: 20200038436
    Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.
    Type: Application
    Filed: April 15, 2019
    Publication date: February 6, 2020
    Inventor: Edward A. NEUWELT
  • Base Medicinal Formulation for Supporting the Specific Homeostatic Acid-Base Balance of Differentiated Living Tissues
    Publication number: 20200038437
    Abstract: This invention is a base medicinal formulation that supports autonomic metabolic mechanisms for maintaining the specific homeostatic acid-base balance of differentiated living tissues in a body by influencing alterations in the anion gap and transitionally buffering acid in support of pH balance in arterial blood plasma in the narrow alkaline range of 7.37 to 7.43.
    Type: Application
    Filed: August 4, 2018
    Publication date: February 6, 2020
    Inventor: Lawrence M. Green